Investigate the effect of AZD1656 on the pharmacokinetics of Pioglitazone and vice versa in Type 2 Diabetes Mellitus
Study identifier:D1020C00028
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Open, Randomized, Phase I Study in Subjects with Type 2 Diabetes Mellitus Treated with Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1656, Pioglitazone
Sex
All
Actual Enrollment
28
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Feb 2010
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15 | Drug: AZD1656 Tablets orally, twice daily for 10 days Drug: Pioglitazone Tablet oral single dose for 10 days |
| Experimental: 2 Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15 | Drug: AZD1656 Tablets orally, twice daily for 10 days Drug: Pioglitazone Tablet oral single dose for 10 days |
Contacts
Investigators
Principal Investigator
Stanko Skrtic
AstraZeneca
